Results for antraciklinima translation from Croatian to English

bolesnici prethodno liječeni antraciklinima
anthracycline pre-treated patients

prethodno liječenje antraciklinima može biti čimbenik rizika za disfunkciju srca.
prior anthracycline therapy may be a risk factor for cardiac dysfunction.

prethodno liječenje antraciklinima može povećati rizik od produljenja qt intervala.
previous treatment with anthracyclines may increase the risk of qt prolongation.

monoterapija kapecitabinom nakon neuspješne kemoterapije taksanima i antraciklinima te u bolesnika u kojih antraciklinska terapija nije indicirana
monotherapy with capecitabine after failure of taxanes, anthracycline containing chemotherapy, and for whom anthracycline therapy is not indicated

docetaksel s trastuzumabom bio je efikasan neovisno o tome jesu li bolesnici prije toga primali adjuvantnu terapiju antraciklinima.
docetaxel plus trastuzumab was efficacious in patients whether or not they had received prior adjuvant anthracyclines.

bolesnici su prethodno primili od 0 do 4 linije liječenja za uznapredovalu bolest, no nisu prethodno bili liječeni antraciklinima.
patients had received 0-4 previous lines of therapy for treatment of advanced disease but had not previously received treatment with anthracyclines.

prethodna izloženost antraciklinima i/ili zračenje stijenke prsnog koša mogući su čimbenici rizika za razvoj kongestivnog zatajenja srca.
prior anthracyclines exposure and/or prior radiation to the chest wall may be possible risk factors for the development of chf.

provedena je faza iii multicentričnog randomiziranog ispitivanja otvorenog tipa kako bi se usporedile monoterapija docetakselom i terapija paklitakselom u liječenju uznapredovalog karcinoma dojke kod bolesnika prethodno liječenih antraciklinima.
an open-label, multicenter, randomized phase iii study was conducted to compare docetaxel monotherapy and paclitaxel in the treatment of advanced breast cancer in patients whose previous therapy should have included an anthracycline.

kao monoterapija za liječenje bolesnika s lokalno uznapredovalim ili metastatskim karcinomom dojke nakon neuspjeha kemoterapijskog protokola koji se sastojao od kombinacije taksana i antraciklina ili u slučajevima u kojima daljnje liječenje antraciklinima nije indicirano.
as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.

aktivna ili pritajena kardiovaskularna bolest, ranija terapija antraciklinima ili antracenedionima, ranija ili istovremena terapija zračenjem medijastinalnog područja ili istovremena primjena drugih kardiotoksičnih lijekova mogu povećati rizik za kardiotoksičnost.
active or dormant cardiovascular disease, prior therapy with anthracyclines or anthracenediones, prior or concurrent radiotherapy to the mediastinal area, or concurrent use of other cardiotoxic medicinal products may increase the risk of cardiac toxicity.

gore spomenute pretrage i postupci praćenja rada srca tijekom liječenja antraciklinima primjenjuju se sljedećim redoslijedom: ekg pregled, mjerenje ejekcijske frakcije lijeve klijetke, biopsija endomiokarda.
the evaluation tests and methods mentioned above concerning the monitoring of cardiac performance during anthracycline therapy are to be employed in the following order: ecg monitoring, measurement of left ventricular ejection fraction, endomyocardial biopsy.

kapecitabin je u kombinaciji s docetakselom (vidjeti dio 5.1) indiciran u liječenju bolesnika s lokalno uznapredovalim ili metastatskim karcinomom dojke nakon neuspjeha citotoksične kemoterapije antraciklinima.
capecitabine in combination with docetaxel (see section 5.1) is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy.

kapecitabin sun koristi se u kombinaciji s docetakselom (drugim antikancerogenim lijekom) nakon neuspješne terapije antraciklinima (drugi tip antikancerogenog lijeka).
capecitabine sun is used with docetaxel (another anticancer medicine) after treatment with anthracyclines (another type of anticancer medicine) has failed.

lartruvo je ispitivan u jednom glavnom ispitivanju koje je uključivalo 133 odrasla bolesnika s uznapredovalim sarkomom mekog tkiva koji nisu mogli biti podvrgnuti kirurškom zahvatu ili radioterapiji i koji prije nisu bili liječeni antraciklinima (skupina lijekova protiv raka koja uključuje doksorubicin).
lartruvo has been investigated in one main study involving 133 adults with advanced soft tissue sarcoma who couldn’t undergo surgery or radiotherapy and who had not been previously treated with anthracyclines (a group of cancer medicines that includes doxorubicin).

abraxane je indiciran u odraslih kao monoterapija za liječenje metastatskog karcinoma dojke kod bolesnika koji nisu reagirali na prvu liniju liječenja za metastatsku bolest, i za koje nije indicirana standardna terapija antraciklinima (vidjeti dio 4.4).
abraxane monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated (see section 4.4).